16-NOV-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3809 280 175 101 25 2 02/06/2019 467 187
Screened at PD     1358 119 94 56 14 1      
Pre-Screened prior to PD     2438 148 72 41 9 1      
Treatment-naive     13 13 9 4 2 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     518 23 13 9 4 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2022 273 132 72 28 10      
Screened at PD     1129 140 90 53 19 5      
Pre-Screened prior to PD     825 117 33 15 7 3      
Treatment-naive     13 13 9 4 2 2      
After PD on a Lung_MAP Sub-Study     55 3 0 0 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     240 240 115 63 26 8      
S1900G     32 5 2 1 0 0      
S1900J     14 6 3 2 0 0      
S1900K     26 20 12 6 2 2      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     550 59 46 30 11 3      
Initial sub-study registrations     538 59 46 30 11 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 35 35 35 24 9 1 05/22/2025 325 102
Docetaxel plus Ramucirumab Y   19 19 19 13 5 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   16 16 16 11 4 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 22 6 2 1 0 0 05/05/2023 295 106
Capmatinib + Osimertinib + Ramucirumab Y   12 5 2 1 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 3 1 1 0 0 11/19/2024 236 77
Amivantamab Hyaluronidase Y   3 3 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 16 14 8 4 2 2 08/08/2024 275 91
Tepotinib + Ramucirumab Y   10 9 4 2 1 1      
Tepotinib Y   6 5 4 2 1 1